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WORKSHOP OBJECTIVE: The purpose of this work-
shop is to enhance decision-making skills by successfully
applying pharmacoeconomic assessments and the exami-
nation of outcomes research specific to the community
healthcare facility.
PARTICIPANTS WHO WOULD BENEFIT: Health-
care professionals and decision-makers who provide
healthcare from community healthcare facilities.
Community healthcare providers can greatly enhance pa-
tient focused and economic outcomes by performing
their own pharmacoeconomic and outcome studies. Most
community healthcare facilities make decisions based
upon other previous studies that may not reflect their pa-
tient population, community or economic model. This
workshop will enable the participant to identify and ob-
tain vital information that is specific for their facility and
patient population. Incorporating this data into the deci-
sion process will result in developing policy that is more
effective for their facility and community.
WMM5
USING EPIDEMIOLOGIC DATABASES TO 
EXTRAPOLATE LONG-TERM OUTCOMES FROM 
SURROGATE MARKER DATA
Huse DM, Russell, MW
Medical Research International, Burlington, MA, USA
WORKSHOP OBJECTIVE: The purpose of this work-
shop is to review the methodological issues involved in
the development of pharmacoeconomic models for pre-
ventive interventions or chronic disease treatments when
the drug’s effects are observed over relatively short time
frames (as in most clinical trials).
PARTICIPANTS WHO WOULD BENEFIT: Research-
ers who want to understand how external sources of epi-
demiologic data can be used in conjunction with “surro-
gate marker” data from clinical trials to infer long-term
patient outcomes.
The extended duration of follow-up in large-scale “event”
trials permits researchers to document a drug’s proximal
effects on key biologic measures or “surrogate markers”
and to attribute improvements in long-term patient out-
comes to the drug’s effect on the surrogate marker(s).
While the ability to link short-term effects with long-term
outcomes within a clinical trial is desirable, such studies
are frequently cost-prohibitive. Despite the lack of long-
term follow-up in traditional drug efficacy trials, it is still
possible in many cases to make inferences about a drug’s
long-term effects on patient outcomes. In this workshop,
we will illustrate how statistical models of the relationship
between surrogate markers and outcomes can be devel-
oped using epidemiologic databases, and how these mod-
els can be used in conjunction with surrogate marker and
cost data to estimate long-term clinical and economic con-
sequences of drug therapy. The importance of appropriate
patient identification and selection criteria in epidemio-
logic research will be stressed. A case study will be pre-
sented in which cardiovascular risk equations derived
from the Framingham Heart Study database are used to
estimate reductions in cardiovascular event occurrence
over 1-, 5-, and 10-year time horizons resulting from dec-
rements in diastolic blood pressure (a common surrogate
marker in clinical trials of anti-hypertensive medications).
WMS2
PITFALLS WHEN USING REGRESSION 
EQUATIONS TO ESTIMATE TREATMENT 
IMPACT IN ACTUAL PRACTICE
Caro JJ, Huybrechts KF, Klittich WS
Caro Research, Boston, MA, USA
WORKSHOP OBJECTIVE: To demonstrate how regres-
sion equations should and should not be used when esti-
mating the impact of treatment in actual practice.
PARTICIPANTS WHO WOULD BENEFIT: Research-
ers interested in using regression equations in economic
models.
Short of local trials, researchers often resort to using risk
equations, derived from large epidemiological or clinical
studies, to forecast the costs and health consequences of a
new treatment in their target population. In many cases,
the mean risk factor values for the target population are
included directly in the risk equation to calculate the “av-
erage” likelihood of disease for that population. This
common approach may however not be justified, as we
will demonstrate in this workshop, using examples based
on the West of Scotland Coronary Prevention Study. The
results derived in this way do not properly reflect the
clustering of risk factors in the population and are very li-
able to give incorrect outcomes. Instead, epidemiological
studies that contain information on the joint risk factor
distribution in a large number of patients, representative
of the target population, should be identified. These pa-
tient level data should be used to simulate individuals one
at a time and the average risk for the cohort should be
derived as the mean of the individuals’ results. Despite
the increased effort required, this is the only proper tech-
nique to accurately predict the effects of treatment in a
population different from the one used to derive the
equations.
WMS5
ASSESSING THE GENERALIZABILITY OF THE 
RESULTS OF MULTINATIONAL TRIALS FOR 
INDIVIDUAL COUNTRIES PARTICIPATING 
IN THE TRIAL
Glick H, Polsky D
University of Pennsylvania, Philadelphia, PA, USA
WORKSHOP OBJECTIVE: The purpose of this work-
shop will be to discuss methods for evaluating the gener-
alizability of results from multinational trials. We will
